MARKET

ARWR

ARWR

Arrowhead Pharma
NASDAQ
78.89
-0.38
-0.48%
After Hours: 78.89 0 0.00% 17:27 06/26 EDT
OPEN
78.94
PREV CLOSE
79.27
HIGH
82.30
LOW
77.45
VOLUME
18.92M
TURNOVER
--
52 WEEK HIGH
84.55
52 WEEK LOW
14.30
MARKET CAP
11.11B
P/E (TTM)
-36.7666
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Top Healthcare Picks: Eton Pharmaceuticals (ETON), Arrowhead Pharmaceuticals (ARWR)
TipRanks · 1d ago
10 large and mega-cap U.S. healthcare stocks with the strongest momentum grades
Seeking Alpha · 4d ago
Arrowhead receives MAA in the EU for REDEMPLO
TipRanks · 5d ago
Arrowhead Pharmaceuticals Receives European Commission Marketing Authorization For REDEMPLO To Lower Triglyceride Levels In Adult Patients With Familial Chylomicronemia Syndrome
Benzinga · 5d ago
Arrowhead says EU grants marketing authorization for REDEMPLO in adult FCS patients
PUBT · 5d ago
ARROWHEAD PHARMACEUTICALS RECEIVES MARKETING AUTHORIZATION IN THE EUROPEAN UNION FOR REDEMPLO® (PLOZASIRAN) TO REDUCE TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)
Reuters · 5d ago
Weekly Report: what happened at ARWR last week (0615-0619)?
Weekly Report · 6d ago
Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update
Simply Wall St · 06/20 06:26
More
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.

Webull offers Arrowhead Pharmaceuticals Inc stock information, including NASDAQ: ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.